|
|||||
|
|
Progress in immunotherapy for small cell lung cancer |
|
| Authors: | Dong Zhao Bing Xie Yong Yang Peng Yan Sheng-Nan Liang Qiang Lin |
| Affiliation: | Dong Zhao, Bing Xie, Yong Yang, Peng Yan, Sheng-Nan Liang, Department of Oncology, The People’s Hospital of Lixin County, Bozhou 236700, Anhui Province, ChinaQiang Lin, Department of Oncology, North China Petroleum Bureau General Hospital, Hebei Medical University, Renqiu 062552, Hebei Province, China |
| Abstract: | Small-cell lung cancer (SCLC) is a special type of lung cancer that belongs to highly aggressive neuroendocrine tumors. At present, radiotherapy and chemotherapy remain the mainstay of treatment for SCLC. Progress in targeted therapies for SCLC with driver mutations has been slow, and these therapies are still under investigation in preclinical or early-phase clinical trials, and research on antiangiogenic tyrosine kinase inhibitors (e.g., anlotinib) has achieved some success. Immunotherapy is becoming an important treatment strategy for SCLC after radiotherapy and chemotherapy. In this article we review the recent advances in immunotherapy for SCLC. |
| Keywords: | Small-cell lung cancer Programmed death-1 inhibitors Cytotoxic T lymphocyte-associated antigen-4 inhibitors Poly adenosine diphosphate ribose polymerase inhibitors |
| 点击此处可从《World journal of clinical oncology》浏览原始摘要信息 | |